VISIONHEALTH

Optimizing inhaled therapies

Non-confidential company introductory presentation April 2024




15

VISIONHEALTH



Kata



@VisionHealth

We develop innovative, patient-centric digital health solutions that target more efficient inhaled drug delivery, leading to better clinical outcomes & patient quality of life.

Our Kata[®] product redefines adherence and disease management with real-time intervention and data analytics



WHY KATA®?

Kata[®] ensures better clinical outcome for patients by efficient inhaled drug delivery



De-risk your clinical program and your commercial launch & Deliver patient insights in real-time from the patient's home



The most effective drug in the world only provides full benefits if delivered correctly.

THE MOST EFFECTIVE DRUG IN THE WORLD ONLY PROVIDES FULL BENEFITS IF DELIVERED CORRECTLY


Patients need to use inhaler devices correctly:

The Washington Post Democracy Dies in Darkness	•	g your meds wrong e these common mi	e de la constante de la consta
Inhalation is not easy:	Advice by <u>Trisha Pasricha, MD</u> Contributing columnist February 19, 2024 at 6:00 a.m. EST • Using your inhalers incorrectly. Around 9 out of 10 people using metered-dose <u>inhalers</u> , commonly prescrib asthma or chronic obstructive pulmonary disease, err in technique — such as failing to fire the canister entirely of holding their breath long enough. At your next visit, sho		<u>lers</u> , commonly prescribed for ulmonary disease, err in their re the canister entirely or not
It can be hard to use MDIs correctly. Even when using the best technique, you may only get 25% of what comes out of the MDI into your lungs. This amount. is often still enough to treat your lung condition. However, most people have such difficulty using an MDI that they get even less than 15% from each puff.		doctor how you use it just to ma	Adv Ther (2019) 36:2547-2557 https://doi.org/10.1007/s12325-019-01066-6 COMMENTARY Understanding Dry Powder Inhalers: Key Technical and Patient Preference Attributes Mark L. Levy 💿 · Will Carroll · José L. Izquierdo Alonso · Claus Keller · Federico Lavorini · Lauri Lehtimäki
		owever, poor adherence and incom in inhalation therapy. Most patient	petence with the device remain as ts are able to use nebulisers and




Inhaled therapies can be highly effective but have inherent challenges affecting adherence.

THE MOST EFFECTIVE DRUG IN THE WORLD ONLY PROVIDES FULL BENEFITS IF DELIVERED CORRECTLY



Inhalation is not easy:

- Patients need time-consuming device education
- 50% of inhalations deliver no dose due to incorrect device use,
- Patients inhale at home without supervision & do not receive the full benefit of therapy,
- Results in risk for good clinical outcome



Patients need to use inhaler devices correctly:


- Shorter & more direct way to patient education
- Right inhalation ensures optimal dose,
- Monitors patients' inhalation and symptoms between visits
- Correct inhalation and metrics can stabilize patients and delay stepping up therapy

Kata ensures effective, reproducible drug delivery to the lungs and delivers patients' insights.

HOW DO WE REACH BETTER DELIVERY AND BETTER CLINICAL OUTCOMES?



Video demonstration of Kata[®] -YouTube link: <u>https://youtu.be/HC34qo8pK3g</u>





> Real-time inhalation coach & animated guidance for any inhaler.


> Video and auditory sensors measure quality of inhalation and correct dose delivery to the lungs.

> Stops inhaler misuse and poor inhalation.

> Maximizes therapy outcome & delivers patient insights.

No additional hardware necessary. Kata[®] "only" needs the camera and microphone of the smartphone.

KATA SHOWS A PROVEN BENEFIT IN REDUCING INHALATION ERRORS



Real world patients trained using their inhalation devices

Our data shows:

Training is good, coaching is better.

Using Kata


- > Handling errors down to 0.1 error per inhalation.
- > Critical errors down to 0 errors per inhalation

Melani et al. Respiratory medicine vol. 106,5 (2012): 668-76. Windisch et al. PloS one vol. 13,10. 2018

Industry standard: training by nurses and videos Critical error: no dose delivered when using inhaler




DISEASE MANAGEMENT - BEYOND INHALATION TRAINING



Patient-Centric Digital Therapeutic for all Patients with Chronic Pulmonary Diseases

KATA® OFFERS A UNIQUE DIGITAL SOLUTION FOR INHALED THERAPEUTICS





Kata[®] is the only digital therapeutic that measures the quality of inhalation and coaches patients.

OUR COMPANY AND FOUNDERS

Dr. Sabine Häussermann Chief Executive Officer, Founder Munich, Germany



30 years in respiratory drug delivery, digital health & clinical trial design

Philipp Kroneberg *Chief Operating Officer, Co-Founder Munich, Germany*



20 years in BD in respiratory medicine & in market access of telemedicine

Peter Shadday *Chief Business Officer Boston, USA*



30 years in healthcare as commercial lead; marketing & market access

Hannes Wetscher Chief Finance Officer Munich, Germany



30 years in healthcare as finance lead; CFO of startups

THE COMPANY	 Startup in digital therapeutics, Privately held Founded 2017 in Munich, Germany
	> Established team with strong background in pharma, med-tech and software
	engineering, deep development & market-access know-how in digital health

Together, we have vast experience in pharma, med-tech market-access knowhow in digital health.

OUR REFERENCES



Fortrea



Certified



A Company of Recipharm




Largest German Public Health Insurance



Proud to work with strong national and international partners.

SUMMARY



Poor inhaler technique and poor adherence lead to poor clinical outcome, caused by low/no drug deposition.

With Kata[®] the target drug dose is delivered at every inhalation with personalized, real-time coaching.

Katas AI algorithm can be easily adapted to each inhaler. Kata offers many other remote patient monitoring features.

Together we can help patients achieve better outcomes by providing a more direct disease management option and empower them.

The Kata[®] App ensures the intended drug dose delivery to the lungs, optimizes patient education, tracks patient reported outcomes & insights for home-inhaled therapies.

WE LOOK FORWARD TO HEARING FROM YOU

Digital therapeutics changes the way we deliver healthcare to patients.

VisionHealth GmbH Landsberger Strasse 72 80339 München Germany

Peter Shadday +1 857 243 0728

Peter.shadday@visionhealth.gmbh www.visionhealth.gmbh





REFERENCES DRUG DELIVERY TO THE LUNGS

Normansell R, Kew KM, Mathioudakis AG. Interventions to improve inhaler technique for people with asthma. Cochrane Database Syst Rev. 2017 Mar 13;3(3):CD012286. doi: 10.1002/14651858.CD012286.pub2. PMID: 28288272; PMCID: PMC6473469.

Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care. 2005 Oct;50(10):1360-74; discussion 1374-5. PMID: 16185371.

Roggeri A, Micheletto C, Roggeri DP. Inhalation errors due to device switch in patients with chronic obstructivepulmonary diseaseand asthma: critical health and economicissues. Int J Chron Obstruct Pulmon Dis. 2016 Mar 21;11:597-602. doi: 10.2147/COPD.S103335. PMID: 27051283; PMCID: PMC4807897.

Sulaiman I, Greene G, MacHale E, Seheult J, Mokoka M, D'Arcy S, Taylor T, Murphy DM, Hunt E, Lane SJ, Diette GB, FitzGerald JM, Boland F, Sartini Bhreathnach A, Cushen B, Reilly RB, Doyle F, Costello RW. A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma. Eur Respir J. 2018 Jan 4;51(1):1701126. doi: 10.1183/13993003.01126-2017. PMID: 29301919.

O'Dwyer S, Greene G, MacHale E, Cushen B, Sulaiman I, Boland F, Bosnic-Anticevich S, Mokoka MC, Reilly RB, Taylor T, Ryder SA, Costello RW. Personalized Biofeedback on Inhaler Adherence and Technique by Community Pharmacists: ACluster Randomized Clinical Trial. J Allergy Clin Immunol Pract. 2020 Feb;8(2):635-644. doi: 10.1016/j.jaip.2019.008. Epub 2019 Sep 27. PMID: 31568927.

Morton RW, Elphick HE, Rigby AS, Daw WJ, King DA, Smith LJ, Everard ML. STAAR: a randomised controlled trial of electronic adherencemonitoring with reminder alarms and feedback to improve clinical outcomes for children with asthma. Thorax. 2017 Apr;72(4):347-354. doi: 10.1136/thoraxjnl-2015-208171. Epub 2016 Nov 4. PMID: 27815524.

Duerden, M., Price, D. Training Issues in the Use of Inhalers. Dis-Manage-Health-Outcomes 9, 75–87 (2001). https://doi.org/10.2165/00115677-200109020-00002

Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, Corrigan C, Levy M, Crompton GK. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008 Apr;102(4):593-604. doi: 10.1016/j.rmed.2007.11.003. Epub 2007 Dec 20. PMID: 18083019.

Takaku Y, Kurashima K, Ohta C, Ishiguro T, Kagiyama N, Yanagisawa T, Takayanagi N. How many instructions are required to correct inhalation errors in patients with asthma and chronic obstructive pulmonary disease? Respir Med. 2017 Feb;123:110-115. doi: 10.1016/j.rmed.2016.12.012. Epub 2016 Dec 21. PMID: 28137486.

Inhaler Error Steering Committee; Price D, Bosnic-Anticevich S, Briggs A, Chrystyn H, Rand C, Scheuch G, Bousquet J. Inhalercompetence in asthma: common errors, barriers to use and recommended solutions. Respir Med. 2013 Jan;107(1):37-46. doi: 10.1016/j.rmed.2012.09.017. Epub 2012 Oct 23. PMID: 23098685.

Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013 Oct;107(10):1481-90. doi: 10.1016/j.rmed.2013.04.005. Epub 2013 May 3. PMID: 23643487.

Hale EM, Greene G, Mulvey C, Mokoka MC, van Boven JFM, Cushen B, Sulaiman I, Brennan V, Lombard L, Walsh J, Plunkett S, McCartan TA, Kerr PJ, Reilly RB, Hughes C, Kent BD, Jackson DJ, Butler M, Counihan I, Hayes J, Faul J, Kelly M, Convery R, Nanzer AM, Fitzgerald JM, Murphy DM, Heaney LG, Costello RW; INCA Research Team. Use of digital measurement of medication adherenceand lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial. Lancet Respir Med. 2023 Jul;11(7):591-601. doi: 10.1016/S2213-2600(22)00534-3. Epub 2023 Mar 21. Erratum in: Lancet Respir Med. 2023 May;11(5):e47. PMID: 36963417.

van de Hei SJ, Kim CH, Honkoop PJ, Sont JK, Schemer TRJ, MacHale E, Costello RW, Kocks JWH, Postma MJ, van Boven JFM. Long-term cost-effectiveness of digital inhaler adherence technologies in difficult-to-treatasthma. J Allergy Clin Immunol Pract. 2023 Jul 3:S2213-2198(23)00716-X. doi: 10.1016/j.jaip.2023.06.051. Epub ahead ofprint. PMID: 37406806.

